Improving stroke victims' prospects

Article

NovaVision's Vision Restoration Therapy (VRT) offers an effective rehabilitation intervention for patients with visual field defects resulting from stroke and traumatic brain injury, according to data presented at the 2007 International Stroke Conference, San Francisco, USA.

NovaVision's Vision Restoration Therapy (VRT) offers an effective rehabilitation intervention for patients with visual field defects resulting from stroke and traumatic brain injury, according to data presented at the 2007 International Stroke Conference, San Francisco, USA.

Of the 161 subject participants who underwent a six–module course (one module represents four weeks of therapy), 122 demonstrated a 3% or greater improvement in stimulus detection on visual field testing. Although functional outcomes were not measured in this particular study, previous studies have suggested that people who regain 3% or more of their visual field have functional improvements that may help enhance their quality of life.

NovaVision VRT is the only FDA cleared, non–invasive medical device that can enhance vision in people who have been left partially blind due to stroke or brain trauma.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.